Status:
TERMINATED
Effect of Spinal Ketorolac After Acute Opioid Exposure
Lead Sponsor:
Wake Forest University
Collaborating Sponsors:
National Institute of General Medical Sciences (NIGMS)
Conditions:
Healthy
Eligibility:
All Genders
18-55 years
Phase:
PHASE2
Brief Summary
This research study is being done because pain is a significant problem for patients with a variety of medical problems and following surgery or traumatic injury. Currently available pain medications ...
Detailed Description
Intravenous (IV) remifentanil stimulates spinal COX activity, leading to increased Cerebrospinal fluid CSF) prostaglandin E2 (PGE2) concentrations and areas of capsaicin-induced mechanical hypersensit...
Eligibility Criteria
Inclusion
- healthy
- American Society of Anesthesiologist (ASA) I or II classification
- between the ages of 18-55
- weigh less than 250 pounds
- without chronic pain
Exclusion
- taking analgesics in the last 2 weeks
- positive urine drug screen
- pregnancy
- currently taking any prescription antidepressants or other medications that are mood altering
- liver or kidney disease
- stomach ulcers
- allergies to ketorolac, lidocaine, or capsaicin cream
- lung disease (COPD)
Key Trial Info
Start Date :
December 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2011
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT00693160
Start Date
December 1 2007
End Date
January 1 2011
Last Update
September 7 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wake Forest University Health Sciences
Winston-Salem, North Carolina, United States, 27157